Abstract
Normal pressure hydrocephalus is a common cause of gait and cognitive impairment in later life, characterised by accumulation of excessive cerebrospinal fluid (CSF). Clinical improvement can occur following CSF diversion. No biomarkers are available to mechanistically investigate fluid accumulation, support diagnosis or predict response to CSF diversion. We developed a stable isotope labeling kinetics (SILK) method to capture the function of the main site of production of CSF in humans, the choroid plexus (ChP), in vitro and in vivo. We captured ChP protein kinetics in human ChP organoids and the CSF of participants with suspected NPH undergoing CSF drainage (n=10) or controls (n=9). We found that transthyretin is abundantly secreted by ChP organoids, and we observe correlations with CSF transthyretin synthesis rates and volume of CSF production in vivo (ρ=0.738; p<0.05). Clearance rates of transthyretin are ∼10 fold slower in NPH compared to controls, demonstrating impaired CSF clearance. ChP SILK is a novel clinical tool for interrogating CSF flow.
One Sentence Summary: Using stable isotope labeling kinetics of choroid plexus proteins, in human choroid plexus organoids and in vivo, we find that synthesis and clearance of transthyretin is altered in normal pressure hydrocephalus.
Competing Interest Statement
KM is a shareholder of Guilford Street Laboratories Ltd. RJB has received research funding from Avid Radiopharmaceuticals, Janssen, Roche/Genentech, Eli Lilly, Eisai, Biogen, AbbVie, Bristol Myers Squibb, and Novartis. Washington University and RJB have equity ownership interest in C2N Diagnostics and receive income based on technology (stable isotope labeling kinetics, blood plasma assay, methods of diagnosing AD with phosphorylation changes, neurofilament light chain assays and materials) licensed by Washington University to C2N Diagnostics. RJB receives income from C2N Diagnostics for serving on the scientific advisory board. RJB serves as an unpaid member on scientific advisory boards for Roche and Biogen.
Funding Statement
RWP is the recipient of an Alzheimer's Association Clinician Scientist fellowship AACSF-20-685780, Alzheimer's disease Part the Cloud award PTC-22-982162 and a Rosetrees Race Against Dementia Team award supported by the Q Charitable Trust. He is supported by the UCLH Queen Square BRC. TAG was supported by research funding from the Alzheimer's Association (23AARFD-1029918).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NHS Health Research Authority, Research Ethics Committee London-Bloomsbury gave ethical approval for the UCL NPH SILK study. All individuals provided informed written consent. Individuals with suspected idiopathic normal pressure hydrocephalus were recruited from the specialist hydrocephalus service at the National Hospital for Neurology and Neurosurgery, Queen Square.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos